NCT07280572

RECLAIM Adaptive Platform Trial for PCC Treatments

RECLAIM: an Adaptive Platform Trial for the Evaluation of Treatments for Post-Acute Sequelae of SARS-CoV-2 Infection (PASC)

• Status: Enrolling By Invitation
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 1,250 (estimated)
• Sponsor: Janneke van de Wijgert · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

RECLAIM is a Phase III, multi-domain, randomized, controlled, adaptive platform trial, designed to evaluate efficacy and safety of repurposed medications in patients with post-COVID condition (PCC). The trial started in the Netherlands in February 2025, comparing metformin, colchicine and usual care in an open-label domain. The information in this registration concerns that first domain in the Netherlands. A second domain, comparing minocyclin to a matching placebo, is expected to start in January 2026, also in the Netherlands. Trial-arms, additional domains and implementing countries may be introduced or terminated as the trial progresses. Participation is fully remote, using electronic consenting, video consultations and home delivery of medication. Default IP use is 12 weeks with biweekly online follow-up questionnaires between Day-1 and Week-12, and one final follow-up questionnaire at week-24.

Conditions

• Post COVID Condition

Interventions

Type	Name	Description
DRUG	Metformin	Participants receive metformin tablets for a period of 12-weeks.
DRUG	colchicine	Participants receive colchicine tablets for a period of 12-weeks.

Timeline

• Start date: 2025-02-17
• Primary completion: 2027-12-01
• Completion: 2027-12-01
• First posted: 2025-12-12
• Last updated: 2025-12-12

Locations

1 site across 1 country: Netherlands